THE ABRAXANE PIVOTAL PHASE III TRIAL INCLUDED OVER 1000
PATIENTS WITH ADVANCED SQUAMOUS AND NONSQUAMOUS NSCLC

Advanced Non-Small Cell Lung Cancer (NSCLC) Phase III trial design - chart Advanced Non-Small Cell Lung Cancer (NSCLC) Phase III trial design - chart

Treatment administered until disease progression or development of unacceptable toxicity

*The efficacy and safety of ABRAXANE + carboplatin based on PD-L1 status have not been established.


Studied in a broad range of chemonaïve patients with advanced NSCLC
Studied in a broad range of chemonaïve patients with advanced NSCLC
Stratified by histologies and age 11,12

ABRAXANE + carboplatin arm (n=521)

Advanced Non-Small Cell Lung Cancer (NSCLC) study patient charactaristics - chart Advanced Non-Small Cell Lung Cancer (NSCLC) study patient charactaristics - chart


Three-quarters of the patients had a history of smoking 11
Three-quarters of the patients
had a history of smoking 11

ABRAXANE + carboplatin arm (n=519) a

Advanced Non-Small Cell Lung Cancer (NSCLC) patients smoking history - icon Advanced Non-Small Cell Lung Cancer (NSCLC) patients smoking history - icon

  • aThe smoking status was unknown for 2 patients in the ABRAXANE + carboplatin arm.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL